4Front Ventures Corp. cultivates, processes, manufactures, and sells cannabis products in the U.S. Key concerns include a low market cap of $4.58M, negative EBITDA and net margins, indicating operational challenges. Additionally, a current ratio of 0.34 and quick ratio of 0.16 suggest liquidity issues. While the gross margin of 21.4% shows potential profitability, the overall financial health score of 11/100 raises significant red flags, indicating the company may struggle to sustain operations without improvement.
Loading financial metrics...
Revenue fell 34.6% year-over-year from $115.7M to $75.6M. The decline has persisted for multiple quarters.
Company posted a loss of $-36.4M over the last year, representing 48.1% of revenue.
Debt of $214.1M is 171.9x the company's cash position of $1.2M.
Gross margin expanded by 9.5 percentage points, indicating improved pricing power or cost efficiency.
Both gross margin (+9.5pp) and operating margin (+2.7pp) are expanding simultaneously, indicating the company is scaling profitably.
Operating margin increased by 2.7pp, reflecting better cost management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2024-Q3 (September 30, 2024)